Will be hosting an informational webinar on Wednesday, April 3. Rakovina Therapeutics Inc. shares V.RKV ...
VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company...
VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company...
VANCOUVER, British Columbia, April 27, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company...
VANCOUVER, British Columbia, April 14, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV), a biopharmaceutical company committed to advancing...
VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company...
Company will highlight new data with kt-3000 lead candidates as a potential treatment for Ewing sarcoma...
VANCOUVER, British Columbia, March 09, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company...
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company...
VANCOUVER, British Columbia, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company...